4IPH fundamentals
An in-depth look to INNATE PHARMA operating, investing, and financing activities
4IPH free cash flow for H1 24 is 2.75 M EUR. For 2023, 4IPH free cash flow was -32.91 M EUR and operating cash flow was -32.56 M EUR.
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: EUR
TTM